Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics 披露了研究人員贊助的針對難治性視網膜母細胞瘤兒科患者的玻璃體內 VCN-01 的 1 期試驗的積極數據
Theriva Biologics Disclosed Positive Topline Data From Investigator Sponsored Phase 1 Trial Of Intravitreal VCN-01 In Pediatric Patients With Refractory Retinoblastoma
Theriva Biologics 披露了研究人員贊助的針對難治性視網膜母細胞瘤兒科患者的玻璃體內 VCN-01 的 1 期試驗的積極數據
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。